{"id":"W4386915712","doi":"10.1200/jco.23.01423","title":"Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":69,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University","funders":"","keywords":"Medicine; Clinical endpoint; Anticancer drug; Oncology; End point; Progression-free survival; Overall survival; Internal medicine; Pharmacology; Drug; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":["metaresearch"],"domain":"methods","study_design":"theoretical_or_conceptual","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":["metaresearch"],"domain":"evaluation","study_design":"theoretical_or_conceptual","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"high","status":"direct model label, unvalidated"}],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.1233125,0.0001473209,0.002651189,0.0003189152,0.00008067083,0.0000237767,0.0004860316,0.0004598584,0.0002866598],"category_scores_gemma":[0.07506128,0.0001476001,0.0005771283,0.0002168426,0.0002281868,0.0003714625,0.00008784647,0.000479843,0.000100156],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003795417,"about_ca_system_score_gemma":0.002073948,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000111037,"about_ca_topic_score_gemma":0.0001088039,"domain_scores_codex":[0.9854919,0.0007570729,0.01258504,0.0003504319,0.0004747137,0.0003407837],"domain_scores_gemma":[0.9600348,0.02529831,0.01357242,0.0004506531,0.0003618054,0.0002820356],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.005058636,0.002828878,0.09595671,0.001725449,0.001272955,0.00004958593,0.004000679,0.0003040232,0.0001374776,0.3953239,0.4566545,0.03668721],"study_design_scores_gemma":[0.01837048,0.010451,0.2558966,0.0004088062,0.0001368089,0.0000344673,0.002468024,0.003627585,0.0001171769,0.1816776,0.526209,0.0006024414],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.5164294,0.0003790448,0.001682361,0.4682337,0.004489718,0.0008769155,0.0002431189,0.00002821528,0.007637578],"genre_scores_gemma":[0.9281304,0.0009236385,0.01966686,0.0459278,0.003876698,0.00008559324,0.00004772454,0.00006605336,0.001275227],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4223059,"threshold_uncertainty_score":0.9327299,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.7421747698617622,"score_gpt":0.6165159011575854,"score_spread":0.1256588687041769,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}